Patent Analysis
Patent Analysis
Sale
The nucleic acid-based therapeutics market was valued at USD 5.32 billion in 2023. It is expected to grow at a CAGR of 13.29% during the forecast period of 2024-2032 and attain a market value of USD 11.37 billion by 2032.
The market is expected to grow due to increasing advancements in nucleic acid sequencing and delivery technologies. This technology has huge potential for the development of personalized medicines. The rising demand for these technologies has led to a surge in the number of patent filings in recent years.
The circulating DNA/RNA patent landscape report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for circulating DNA/RNA includes a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within circulating DNA/RNA technologies.
The sequencing of tumor DNA has led to the development of new biomarkers, leading to possibilities for precision oncology. Detection of amplifications, somatic gene mutations, and gene fusions allows the delivery of targeted therapies in several cancer-types including breast cancer, lung cancer, colorectal, and melanoma. Hence, the patent claim language is crucial for the protection of these advanced technologies, and thus patent filings are on the rise.
Circulating DNA and RNA refers to freely circulating DNA and RNA molecule fragments in the blood or other bodily fluids, such as serum, plasma, saliva, or urine. These fragments originate from cells undergoing normal turnover or cell death.
Circulating DNA/RNA can be detected and analyzed using multiple molecular biology techniques, including PCR, digital PCR, and next generation sequencing (NGS). This technique allows for the identification of specific mutations in DNA/RNA sequences. It also provides insights into disease progression, monitoring and assessment of treatment response.
The expanding applications of cDNA/RNA in cancer detection, non-invasive prenatal testing, monitoring treatment response, and studying disease progression has impacted the patent landscape significantly.
Advancements in Detection Technologies such as qPCR and NGS is Expected to Boost the Patent Industry Growth
Innovations in detection technologies such as quantitative PCR, digital PCR, and next-generation sequencing (NGS) have significantly improved the detection efficiency and sensitivity of circulating DNA and RNA. For instance, NGS-based detection has the potential to simultaneously sequence thousands of targets. Patents covering these technologies are crucial for companies, seeking to establish competitive advantages in the market.
Expanding Applications is Expected to Propel Circulating DNA/RNA Patent Industry Growth
The expanding applications for circulating DNA/RNA across a wide range of diseases, including oncology, infectious diseases, prenatal testing, and autoimmune diseases are likely to boost the number of patent applications in coming years.
For instance, in oncology, the presence of the circulating tumor cfDNA and its analysis allows the detection of cancer disease, as well as the monitoring and assessment of treatment response. In prenatal testing, the analysis of fetal cfDNA in maternal blood allows non-invasive prenatal testing, which can investigate chromosomal abnormalities. This method is an alternative to more invasive methods. The patents covering these diverse applications contribute to the growth of the patent landscape.
The report will cover the following sections in detail
Breakup by Technology
Breakup by Indication
The breakup based on technology includes extraction and preparation of circulating DNA/RNA as well as the detection and analysis of these cfDNA/RNA. Circulating DNA/RNA investigations have been conducted with the chosen patent families labelled based on the platforms to which they pertain.
For instance, QIAGEN offers QIAamp circulating nucleic acid kits. It simplifies the isolation and purification of cfDNA and RNA from serum or plasma. The detailed technological data will be provided for all specified segments classified in this report.
The United States is one of the leading jurisdictions for circulating DNA/RNA patents, having around 129,000+ patents. The presence of major companies, well-established healthcare infrastructure, advanced research and development activities and strong legal framework contributes to the regional patent landscape significantly.
Among the players with circulating DNA/RNA patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:
Illumina Inc.
Illumina, Inc., founded in 1998, and headquartered in the United States, engages in the development, manufacturing, and marketing of integrated systems for the analysis of genetic variation and biological function. The company has filed various patents in the field of circulating DNA/RNA.
Novartis AG
Novartis AG, founded in 1996, and headquartered in Switzerland is a global pharmaceutical company, involved in the development of therapies in multiple areas including oncology, respiratory diseases, neurological disorders, and diabetes among others. The company is developing innovative RNA-targeting therapies which have the potential to target and reduce tumours.
Other companies include Nantomics (NantWorks, LLC), Genentech Inc., and Spot Biosystems Ltd, among others.
The circulating DNA/RNA patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by -
Scope of the Report | Details |
Analysis by Technology |
|
Analysis by Indication |
|
Key Players Mentioned |
|
Global Nucleic Acid Amplification Testing Market
Global DNA Sequencing Products Market
Global Cancer Immunotherapy Market
Global Antisense and RNAi Therapeutics Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Introduction
2 Executive Summary
3 Global Nucleic Acid-Based Therapeutics Market Overview
3.1 Global Nucleic Acid-Based Therapeutics Market Historical Value (2017-2023)
3.2 Global Nucleic Acid-Based Therapeutics Market Forecast Value (2024-2032)
4 Global Nucleic Acid-Based Therapeutics Market Segmentation
4.1 Global Nucleic Acid-Based Therapeutics Market Share by Product Type
4.1.1 Market Overview
4.1.2 RNA Interference [RNAi] and Short Interfering RNAs [siRNAs]
4.1.3 Antisense Oligonucleotides (ASOs)
4.1.4 Others
4.2 Global Nucleic Acid-Based Therapeutics Market Share by Indication
4.2.1 Market Overview
4.2.2 Oncology
4.2.3 Infectious Diseases
4.2.4 Prenatal Diagnostics
4.2.5 Transplantation
4.2.6 Cardiovascular Disorders
4.2.7 Others
4.3 Global Nucleic Acid-Based Therapeutics Market Share by End User
4.3.1 Market Overview
4.3.2 Hospital and Clinics
4.3.3 Research and Academic Institute
5 Global Market Dynamics
5.1 Market Drivers and Constraints
5.2 Porter’s Five Forces Analysis
5.3 PESTEL Analysis
5.4 Industry Events, Initiatives, and Trends
5.5 Value Chain Analysis
6 Global Circulating DNA/RNA Patent Landscape Analysis
6.1 Patent Distribution by Publication Year
6.2 Patent Distribution by Application Year
6.3 Patent Distribution by Priority Year
6.4 Analysis by Type of Patent
6.4.1 Granted Patents
6.4.2 Patent Application
6.4.3 Amended Application
6.4.4 Search Report
6.5 Analysis by Legal Status
6.5.1 Active
6.5.2 Pending
6.5.3 Expired/Discontinued
6.6 Analysis by Patent Jurisdiction
6.7 Analysis by Patent Age
6.8 Analysis by Cooperative Patent Classification (CPC) Codes
6.9 Average Time to Publish a Patent
6.9.1 By Entities
6.9.2 By Jurisdiction
6.9.3 By Technology
6.10 Analysis by Type of Entity (Academic and Non-Academic)
6.11 Analysis by Top Applicants
6.12 Analysis by Top Inventors
7 Global Circulating DNA/RNA Patent Analysis by Technology
7.1 Total Patents by Top Technologies
7.2 Time Evolution of Patents by Technology
7.3 Emerging Technologies
7.4 Patent Segmentation, By Application
7.4.1 Time Evolution by Number of Patents
7.4.2 Time Evolution by Number of Patent Families
7.4.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.4.4 Analysis by Top Applicants
7.4.5 Analysis by Top Inventors
7.5 Patent Segmentation, By Technologies
*Complete technology list will be provided in the report.
8 EMR Patent Valuation Analysis
8.1 Assessment Methodology
8.2 High Value Patents
8.3 Medium Value Patents
8.4 Low Value Patents
9 Global Circulating DNA/RNA – Top 10 Players Patent Analysis
9.1 Top 10 Entities by Number of Patents
9.2 Analysis by Publication Year
9.3 Analysis by Application Year
9.4 Analysis by Priority Year
9.5 Analysis by Type of Patent
9.6 Analysis by Jurisdiction
9.7 Analysis by Cooperative Patent Classification (CPC) Codes
9.8 Analysis by Source of Innovation
9.9 Analysis by Forward and Backward Citations
9.10 Analysis by Legal Status
9.11 Analysis by Patent Age
9.12 Analysis by Key Inventors
9.13 Entity Dynamics
9.13.1 Analysis by Type of Player (Academic vs Non-Academic)
9.13.2 Analysis by Collaboration
9.13.3 Analysis by Technology
9.13.4 Newcomers
9.13.4.1 Start-up Companies
9.13.4.2 Established Companies
10 Patent Profile of Key Players
10.1 Nantomics (NantWorks, LLC)
10.1.1 Product Portfolio
10.1.2 Patent Portfolio by Patent Families
10.1.3 Time Evolution of Patents
10.1.4 Geographical Patent Coverage
10.1.5 Patent Analysis by Technology
10.1.6 Patent News and Developments
10.1.7 Financial Analysis
10.1.8 SWOT Analysis
10.2 Genentech Inc.
10.3 Novartis AG,
10.4 Spot Biosystems Ltd
10.5 Illumina Inc .
11 Future Trends
12 Global Nucleic Acid-based Therapeutics Market Landscape (Additional Insight) *
12.1 Global Nucleic Acid-based Therapeutics: Developers Landscape
12.1.1 Analysis by Year of Establishment
12.1.2 Analysis by Company Size
12.1.3 Analysis by Region
12.2 Global Nucleic Acid-based Therapeutics: Product Landscape
12.2.1 Analysis by Product Type
12.2.2 Analysis by Indication
*Additional insights are not provided in the standard report.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.